Intra-Cellular Therapies Inc (NAS:ITCI)
$ 84.85 -1.15 (-1.34%) Market Cap: 9.00 Bil Enterprise Value: 8.13 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 61/100

Q3 2022 Intra-Cellular Therapies Inc Earnings Call Transcript

Nov 03, 2022 / 12:30PM GMT
Release Date Price: $51.88 (+13.20%)
Operator

Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies Third Quarter Earnings Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I'd now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations.

Juan Fernando Sanchez
Intra-Cellular Therapies, Inc. - VP of Corporate Communications & IR

Good morning, and thank you all for joining us on the call today. Our earnings press release provides a corporate update and details of the company's financial results for the third quarter ended September 30th, 2022. This press release class award this morning and is available on our website at intracellulartherapies.com.

Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Dr. Suresh Durgam, Executive Vice President and Chief Medical Officer; and Larry Hineline, Senior Vice President and Chief Financial Officer.

As a reminder, during

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot